CC-90001
Sponsors
Celgene Corporation, Celgene
Conditions
FibrosisHealthy SubjectsHealthy VolunteerHealthy VolunteersHeathy VolunteerHepatic ImpairmentIdiopathic Interstitial PneumoniasIdiopathic Pulmonary Fibrosis
Phase 1
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001
CompletedNCT02110420
Start: 2014-02-28End: 2014-09-30Updated: 2014-10-15
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
CompletedNCT02321644
Start: 2014-11-30End: 2015-02-28Updated: 2015-08-19
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
CompletedNCT02510937
Start: 2015-08-05End: 2017-02-06Updated: 2017-04-04
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
CompletedNCT03363815
Start: 2017-12-04End: 2018-07-29Updated: 2019-01-25
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
CompletedNCT03742882
Start: 2018-12-06End: 2019-06-10Updated: 2020-07-27
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
CompletedNCT03958864
Start: 2019-04-04End: 2019-06-13Updated: 2020-05-08
Phase 2
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
TerminatedNCT03142191
Start: 2017-07-26End: 2021-12-24Updated: 2023-06-28
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
TerminatedNCT04048876
Start: 2019-08-14End: 2021-09-28Updated: 2023-06-07